Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Caocci Giovanni, Mulas Olga, Annunziata Mario, Luciano Luigiana, Abruzzese Elisabetta, Bonifacio Massimiliano, Orlandi Ester Maria, Albano Francesco, Galimberti Sara, Iurlo Alessandra, Pregno Patrizia, Sgherza Nicola, Martino Bruno, Binotto Gianni, Castagnetti Fausto, Gozzini Antonella, Bocchia Monica, Fozza Claudio, Stagno Fabio, Simula Maria Pina, De Gregorio Fiorenza, Trawinska Malgorzata Monika, Scaffidi Luigi, Elena Chiara, Attolico Imma, Baratè Claudia, Cattaneo Daniele, Pirillo Francesca, Gugliotta Gabriele, Sicuranza Anna, Molica Matteo, La Nasa Giorgio, Foà Robin, Breccia Massimo
Аннотация
METHODS: We identified 656 consecutive CML patients treated with nilotinib, dasatinib, bosutinib and ponatinib.
RESULTS: The 15-year CV-mortality free survival was 93 ± 2.8%. Age ≥65 years (p = 0.005) and a positive history of CV disease (p = 0.04) were significantly associated with a lower CV-mortality free survival. CV disease accounted for 16.5% and 5% of potential years of life lost (PYLL) in male and female patients, respectively. The standard mortality ratio (SMR) following ischemic heart disease (IHD) was 3.9 in males and 3.8 in female patients, meaning an excess of IHD deaths observed, in comparison with the population of control.
CONCLUSION: Prevention strategies based on CV risk factors, in particular in those patients with a previous history of CV disease, should be considered.